Send to printer »

GEN News Highlights : Sep 19, 2006

Nastech Pharmaceutical's Intranasal Insulin Formulation Enters into Clinical Trial

Nastech Pharmaceutical initiated a Phase I pharmacokinetic study designed to evaluate the safety, bioavailability, and glucose response of Nastech’s rapid-acting intranasal insulin formulation. The study will compare Nastech’s intranasal formulation to an approved injectable product and to a recently approved new dosage form, Exubera® (insulin human [rDNA origin]) Inhalation Powder.

Nastech believes its insulin nasal spray could provide patients with a convenient, needle-free alternative while avoiding possible pulmonary side effects or long-term toxicity associated with the inhalation of insulin.